Bharat Biotech resumes export of Covaxin amid Omicron variant scare

Bharat Biotech resumes export of Covaxin amid Omicron variant scare


Indian vaccine maker Bharat Biotech mentioned on Monday it has resumed export of its COVID-19 shot, Covaxin, and has executed long-pend ing orders in November. 

The Modi authorities on Tuesday, 24 November, had accepted the industrial export of Bharat Biotech’s Covid-19 vaccine.

Bharat Biotech is ready to export 108 lakhs of Covaxin doses commercially amid the growing new coronavirus variant, Omicron, scare. 

Covaxin, India’s first indigenous vaccine for Covid-19, has been discovered to be 77.8 per cent efficient in opposition to the lethal coronavirus, a report revealed in The Lancet lately mentioned.

The Centre will resolve the quantity of vaccine to be exported commercially retaining in thoughts the home availability of vaccines each month. 

Covaxin is ready to be exported to eight nations — Botswana, Paraguay, Vietnam, Myanmar, Philippines, Singapore, Cameroon and the UAE. Botswana in southern Africa is amongst 13 nations the place the Omicron variant of the virus inflicting Covid-19 has been discovered.


The latest scare of Omicron variant , which WHO has categorized as ‘variant of concern’, highlighted the vaccine inequality on the planet. The new coronavirus variant is doubtlessly extra harmful than the Delta variant .

Covaxin, the inactivated whole-virion vaccine, was accepted for emergency use in India on January 3 and was granted an Emergency Use Listing (EUL) by the World Health Organization (WHO) on November 3, 2021.



Subscribe to Mint Newsletters

* Enter a sound electronic mail

* Thank you for subscribing to our publication.

Never miss a narrative! Stay related and knowledgeable with Mint.
our App Now!!

Source link